Episode 436: 3 Questions Your Neurologist Should Be Asking Themselves with Dr. Leorah Freeman Podcast Por  arte de portada

Episode 436: 3 Questions Your Neurologist Should Be Asking Themselves with Dr. Leorah Freeman

Episode 436: 3 Questions Your Neurologist Should Be Asking Themselves with Dr. Leorah Freeman

Escúchala gratis

Ver detalles del espectáculo

OFERTA POR TIEMPO LIMITADO | Obtén 3 meses por US$0.99 al mes

$14.95/mes despues- se aplican términos.
Scientists are expanding our understanding of MS at an unprecedented pace. This week, Dr. Leorah Freeman discusses why, as new discoveries and medications enter clinical practice, neurologists and MS specialists should ask themselves 3 important questions when considering a patient's treatment plan. Dr. Freeman is the Director of the Multiple Sclerosis and Neuroimmunology Center at Dell Medical School at the University of Texas at Austin, where she also leads the MS and Neuroimmunology fellowship program and the MS Imaging and Outcomes Research Laboratory. We'll also tell you about study results that reveal two distinct biologically-informed MS subtypes. We're explaining some of the confusing background to the FDA's decision not to approve a disease-modifying therapy that achieved positive results in its Phase 3 clinical trial. And did we really need a study to tell us that people living with MS fear experiencing a relapse or disease progression? Well, yes. We'll explain why. We're also reminding you to mail your insurance premium payments and other important documents earlier than you have in the past. And we're sharing details about the two clinical trials that received $4.1 million in funding as part of the International Progressive MS Alliance Experimental Medicine Trial Awards. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: 3 questions your neurologist should be asking themselves :22 Public Service Announcement: How the new rule about postmarks could affect your healthcare 1:16 FDA says it's not ready to approve Tolebrutinib 3:16 Study identifies two biologically-informed MS subtypes 6:29 Study results remind us that people with MS fear relapse and progression 10:09 The International Progressive MS Alliance invests $4.1 million in two clinical trials 14:04 Dr. Leorah Freeman discusses why neurologists need to ask themselves 3 important questions when considering a patient's treatment plan 17:18 Share this episode 33:16 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/436 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com The Multiple Sclerosis Insider https://themultiplesclerosisinsider.substack.com STUDY: Combined Magnetic Resonance Imaging and Serum Analysis Reveals Distinct Multiple Sclerosis Types https://academic.oup.com/brain/article/148/12/4578/8321558 STUDY: Fear of Disease Progression and Relapse in Multiple Sclerosis: A Systematic Scoping Review https://frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1680781/full JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 436 Guests: Dr. Leorah Freeman Privacy Policy
Todavía no hay opiniones